CHMP5 and COVID-19: In an interim analysis from a phase two randomized, double-blind, placebo-controlled clinical trial involving 452 outpatients with recently diagnosed mild or moderate COVID-19, monoclonal anti-Spike antibody bamlanivimab appeared to accelerate the decline in viral load and provided encouraging results regarding clinical outcomes and COVID-19 related hospitalizations [2,3].